Bioneex

The Founder and CSO of EQUALY sa., Jean-Marie Saint-Remy, is sharing his ground-breaking discovery regarding the potential of the innate immune system to address various disorders. Founded in 2020, EQUALY sa. aims to develop a platform that harnesses this potential by activating natural killer T (NKT) cells specifically designed to recognize and respond to cancer-related antigens, such as those associated with TP53 mutations, which are present in over 60% of human cancers. Their innovative approach enables the creation of cost-effective, off-the-shelf therapies with minimal risk of off-target effects, making them adaptable for different patients with the same detected mutated transcription factor. Would like to learn more? Read the full story https://lnkd.in/eiauF6k5

Bioneex is thrilled to collaborate with GlycoMira Therapeutics, Inc. . GlycoMira Therapeutics, Inc. is pioneering a new class of innate immune system modulators to transform cancer treatment. Their lead candidate, GM-1111, is a first-in-class multi-modal immune modulator with potent anti-tumor, anti-inflammatory, and radioprotective properties. Looking for groundbreaking therapies? Let's connect through Bioneex (https://bioneex.com/) and explore partnership opportunities!

?? This week we are going to share some valuable insights about the UK Biopharma industry. Interested to know the Total UK R&D pipeline size or maybe Top 10 UK-headquartered companies by size of pipeline.? ?? Stay tuned for the weekly insightful reports!

Database stores data - Bioneex drives deals | Database provides information - Bioneex’s AI-powered matchmaking platform actively connects drug development companies with strategic biopharma partners and venture capital investors.

Heegon Kim, the CEO of Renatus is sharing their mission to revolutionize cholesterol modulation with safer and more effective cyclodextrin-based therapies. Their lead candidate, RN-005, features cross-linked cyclodextrins, which are engineered to overcome the safety challenges of traditional cyclodextrins, such as the ototoxicity or “ear poisoning”, while maintaining high efficacy. Shifting their mechanism of action, Renatus' pipeline spans a range of cholesterol-driven diseases including Diabetic kidney diseases, Alzheimer’s, Niemann-Pick Type C or Atherosclerosis among others. Renatus is committed to improving the patient outcomes through its innovative approaches to cholesterol metabolism, making significant strides in tackling cholesterol-driven diseases.

Secure CDAs & Data Rooms on Bioneex! ?? A new feature is coming soon. Confidentiality and secure data sharing are critical in biopharma dealmaking. That’s why Bioneex is launching a new CDA & Data Room feature enabling companies to effortlessly sign CDAs and exchange sensitive documents in a controlled, encrypted environment. ? Instant CDA Execution – Secure, legally binding agreements within minutes ? Confidential Data Sharing – Exchange key documents with full control ? Streamlined Collaboration – Speed up deal negotiations With this feature, Bioneex strengthens its position as the trusted matchmaking platform for biopharma dealmaking.

?? At Bioneex (https://lnkd.in/eyUPKfsc) we connect drug development companies with strategic partners and venture capital investors. We combine the power of AI with the expertise of our scientific team to do customised matchmaking tailored to your needs. Once we find a perfect match, your dedicated scientific manager sends an introductory message to both parties. Then you can take the lead and continue the conversation. Bioneex is a well-structured platform that enables you to run your conversation with potential partners and investors smoothly while also securely sharing confidential information.

?? This week we are going to share some valuable insights about the USA Biopharma industry. Interested to know the USA R&D pipeline size or maybe the Top 10 indications for pipeline drugs? ?? Stay tuned for the weekly insightful reports!

Bioneex connects biotech companies (Providers) and biopharma & VC partners (Seekers) looking to collaborate and scale innovation: As a Seeker on Bioneex, you can: ?? Create company profile ??Search Unlimitedly drug candidates with AI Assistant ??Receive messages ??Do Trial matchmaking Want to benefit more? Become a Seeker Member to: ??Access reviewed drug candidates' detailed information ??Contact Providers ??Receive matchmaking facilitation based on your preferences ??Deal flow automation and updates on your watchlist We believe in innovation, join us at Bioneex (https://lnkd.in/eyUPKfsc) and let the collaboration begin.

At Bioneex we provide a complete and refined data package for each drug candidate asset, which includes: ? Careful review non-confidential information ? Regular updates and improvement suggestions from our scientific team ? Ongoing refinements based on your feedback for optimal matchmaking This ensures you always have the most comprehensive insights with Bioneex ( https://lnkd.in/eyUPKfsc ) to make informed decisions.